Sociedad Americana de Hirudoterapia

Proton bridging in the interactions of thrombin with hirudin and its mimics

Biochemistry article published in Biochemistry (2013)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Research reportFarmacología salivalDesarrollo de fármacosKovach IM, Kakalis L, Jordan F, Zhang D · Biochemistry, 2013

Abstract

Thrombin is the pivotal serine protease enzyme in the blood cascade system and thus a target of drug design for control of its activity. The most efficient nonphysiologic inhibitor of thrombin is hirudin, a naturally occurring small protein. Hirudin and its synthetic mimics employ a range of hydrogen bonding, salt bridging, and hydrophobic interactions with thrombin to achieve tight binding with K(i) values in the nano- to femtomolar range. The one-dimensional (1)H nuclear magnetic resonance spectrum recorded at 600 MHz reveals a resonance 15.33 ppm downfield from silanes in complexes between human α-thrombin and r-hirudin in pH 5.6-8.8 buffers and between 5 and 35 °C. There is also a resonance between 15.17 and 15.54 ppm seen in complexes of human α-thrombin with hirunorm IV, hirunorm V, an Nα(Me)Arg peptide, RGD-hirudin, and Nα-2-naphthylsulfonyl-glycyl-DL-4-amidinophenylalanyl-piperidide acetate salt (NAPAP), while there is no such low-field resonance observed in a complex of porcine trypsin and NAPAP. The chemical shifts suggest that these resonances represent H-bonded environments. H-Donor-acceptor distances in the corresponding H-bonds are estimated to be <2.7 Å. Addition of Phe-Pro-Arg-chloromethylketone (PPACK) to a complex of human α-thrombin with r-hirudin results in an additional signal at 18.03 ppm, which is 0.10 ppm upfield from the observed signal [Kovach, I. M., et al. (2009) Biochemistry 48, 7296-7304] for thrombin covalently modified with PPACK. In contrast, the peak at 15.33 ppm remains unchanged. The fractionation factors for the thrombin-hirudin complexes are near 1.0 within 20% error. The most likely site of the short H-bond in complexes of thrombin with the hirudin family of inhibitors is in the hydrophobic patch of the C-terminus of hirudin where Glu(57') and Glu(58') are embedded and interact with Arg(75) and Arg(77) and their solvate water (on thrombin). Glu(57') and Glu(58') present in the hirudin family of inhibitors make up a key binding epitope of fibrinogen, thrombin's prime substrate, which lends substantial interest to the short hydrogen bond as a binding element at the fibrinogen recognition site.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., Extramural
Indexed MeSH termsAmino Acid SequenceAntithrombinsBinding SitesHirudinsHumansHydrogen BondingModels, MolecularMolecular Sequence DataNuclear Magnetic Resonance, BiomolecularProtonsThrombin

Resumen

1H NMR studies at 600 MHz reveal a short hydrogen-bond network at the C-terminal hirudin-thrombin interface (Glu57', Glu58' to Arg75, Arg77), providing structural insight into hirudin's extremely high affinity for thrombin.

Por qué esto importa para la hirudoterapia

Este estudio utilizó espectroscopia de resonancia magnética nuclear de 600 MHz para investigar enlaces de hidrógeno cortos de campo bajo en complejos entre α-trombina humana y hirudina recombinante, junto con varios miméticos de hirudina (hirunorm IV, hirunorm V, RGD-hirudina) e inhibidores sintéticos de la trombina como NAPAP. Los hallazgos son relevantes porque identifican un elemento de unión puenteado por protones que involucra los residuos Glu(57') y Glu(58') C-terminales de la hirudina interactuando con Arg(75) y Arg(77) en la trombina en el sitio de reconocimiento del fibrinógeno, ofreciendo información mecanística sobre la inhibición de la trombina excepcionalmente potente (K(i) en el rango nano a femtomolar) lograda por la hirudina y sus miméticos. La conexión con la hirudoterapia es solo indirecta: el resumen no hace referencia a sanguijuelas, saliva de sanguijuela o uso terapéutico, caracterizando a la hirudina únicamente como una pequeña proteína natural e inhibidor de la trombina. El estudio se limita al análisis espectroscópico y de modelado molecular de complejos enzima-inhibidor purificados in vitro, sin presentar datos in vivo, clínicos o de organismo completo.

Citación

Proton bridging in the interactions of thrombin with hirudin and its mimics.

Kovach IM, Kakalis L, Jordan F, Zhang D · Biochemistry, 2013

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.